Diabetes, Obesity & Metabolism
However, there are considerable risks, demonstrated by clinical reports, of unappreciated high volumes of gastric contents even when fasting guidelines are followed
Managing the gastrointestinal side effects of GLP-1 receptor agonists in obesity: recommendations for clinical practice
[00:08:14] Emily Field: This does not mean that the medication is directly causing muscle loss
If you feel your appetite suppression is inadequate on your current schedule, talk to your provider about a dose adjustment rather than timing manipulation
Anecdotally, some people who switched from semaglutide to tirzepatide report that their appetite, which had started returning somewhat on semaglutide, decreased again on tirzepatide